However, the survival benefit was shown regardless of PD‐L1 positivity, defined as staining in 1% or more of tumor cells (PD‐L1+: median OS, 5.22 months for nivolumab vs 3.83 months for placebo, HR 0.51; PD‐L1–: median OS, 6.05 months for nivolumab vs 4.19 months for placebo, HR 0.72). The gene discussed is CD274; the disease is neoplasm.